Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 26.06 10.52% 2.48
RVNC closed up 10.52 percent on Friday, August 7, 2020, on 2.05 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical RVNC trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Biopharmaceutical Pain Drugs Plastic Surgery Migraine Toxins Botulinum Toxin Botulism Hyperhidrosis Neurotoxins Rhinitis

Is RVNC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.97
52 Week Low 10.0
Average Volume 534,026
200-Day Moving Average 19.83
50-Day Moving Average 23.82
20-Day Moving Average 24.25
10-Day Moving Average 24.24
Average True Range 1.31
ADX 13.52
+DI 22.24
-DI 13.26
Chandelier Exit (Long, 3 ATRs ) 22.78
Chandelier Exit (Short, 3 ATRs ) 26.74
Upper Bollinger Band 25.56
Lower Bollinger Band 22.95
Percent B (%b) 1.19
BandWidth 10.76
MACD Line 0.15
MACD Signal Line 0.12
MACD Histogram 0.0334
Fundamentals Value
Market Cap 803.15 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -7.58
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.60
Resistance 3 (R3) 31.19 28.95 30.67
Resistance 2 (R2) 28.95 27.54 29.15 30.36
Resistance 1 (R1) 27.50 26.67 28.23 27.91 30.06
Pivot Point 25.26 25.26 25.62 25.46 25.26
Support 1 (S1) 23.81 23.85 24.54 24.22 22.06
Support 2 (S2) 21.57 22.98 21.77 21.76
Support 3 (S3) 20.12 21.57 21.45
Support 4 (S4) 20.53